Feb 21 |
Stifel starts AnaptysBio at buy, cites upcoming catalysts
|
Feb 19 |
Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?
|
Feb 16 |
AnaptysBio gains as Piper Sandler starts at Overweight on catalyst path
|
Feb 12 |
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
|
Jan 31 |
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
|
Jan 13 |
AnaptysBio Inc CEO Daniel Faga Sells 6,866 Shares
|
Nov 23 |
Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug
|
Nov 22 |
MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study
|
Nov 14 |
Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround
|